Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Antony Blinken cancels China trip following discovery of spy balloon
    • How much of a threat are Chinese spy balloons?
    • Nigeria’s attempt to replace its currency notes descends into chaos
    • Madison Square Garden owner battles outcry over ‘dystopian’ blacklisting
    • US jobs total surges by over half a million in January
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • TotalEnergies says exposure to Adani stands at $3.1bn as turmoil mounts
      • Indian authorities seek to calm investors after Adani sell-off
      • EY under fire over its two roles at battery start-up Britishvolt
      • Swiss authorities open criminal probe into bank data breaches
      • Australian battery group selected as preferred bidder for Britishvolt
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Middle-class Britons are the ‘new vulnerable’, says Tyrie
      • UK’s FTSE 100 share index beats 2018 peak to hit all-time high
      • Nigeria’s attempt to replace its currency notes descends into chaos
      • Hedge funds rush to unwind bets on falling markets as stocks surge
      • EU agrees price caps on Russian oil products
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • The worst airport in the world
      • Britain should not accept its status as the ‘sick man of Europe’
      • Tempting back older workers means ditching business as usual
      • Toyota has a tragic flaw in the electric vehicle drama
      • The Tate ruling is a victory against rubbernecking
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Barclays chief: the life lessons I have discovered during cancer treatment
      • Shoshana Zuboff: ‘Privacy has been extinguished. It is now a zombie’
      • A new generation refuses to keep quiet on age discrimination at work
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • After hours with 10 Foot, London’s most notorious graffiti writer
      • Germany grapples with the limits of pacifism
      • Rugby superstar Siya Kolisi: ‘I’ve got no ego at all’
      • Bill Gates is probed and baited in BBC interview with Amol Rajan — TV review
      • My downshift to deepest Spain
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Donato Paolo Mancini

    Pharmaceuticals correspondent

    Donato writes about the drug industry, Covid-19, and international organisations like the WHO. Previously, he worked for The Wall Street Journal and Dow Jones Newswires.
    Email Donato Paolo Mancini @donatopmancini  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Wednesday, 1 February, 2023
      GSK PLC
      GSK bullish on 2023 as earnings surpass expectations

      UK drugmaker’s shingles vaccine boosts sales while demand for Covid-related products falls

    • Tuesday, 24 January, 2023
      News in-depthDrug prices
      Big pharma groups rejoin battle with governments on drug prices

      Tight budgets and US reforms are ending a truce between the industry and health authorities

    • Monday, 9 January, 2023
      CureVac GmbH
      Covid vaccine makers CureVac and Novavax appoint new chiefs

      Pharmaceutical groups to part ways with longstanding executives

    • Thursday, 5 January, 2023
      ExplainerCoronavirus pandemic
      How serious is the threat of new Covid-19 variants?

      A surge in cases after China lifted restrictions has sparked concerns that a dangerous new strain could emerge

    • Wednesday, 4 January, 2023
      Coronavirus pandemic
      China has under-represented its number of Covid deaths, says WHO

      Global health body issues its strongest rebuke yet of Beijing’s handling of the pandemic

    • Wednesday, 21 December, 2022
      Coronavirus pandemic
      WHO urges China to step up vaccinations after rise in Covid cases

      Beijing asked to make more data available on disease severity, hospital admissions and occupancy rates

    • Wednesday, 21 December, 2022
      ExplainerAntibiotic resistance
      Surge in infections leads to global shortage of antibiotics

      Manufacturers struggle to keep pace with post-pandemic demand as dozens of countries report low supply of drugs

    • Monday, 14 November, 2022
      Roche Holding AG
      Roche late-stage Alzheimer’s trials end in failure

      Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

    • Wednesday, 9 November, 2022
      Bavarian Nordic AS
      Bavarian Nordic boosted by monkeypox vaccine

      Price tag of between $70 and $300 a dose helps push Danish biotech to ‘all-time high revenues’

    • Wednesday, 2 November, 2022
      Drugs research
      Magic mushrooms study finds ‘significant’ effect on depression

      UK-led research paves way for regulatory approval of active ingredient psilocybin

    • Wednesday, 2 November, 2022
      US opioid epidemic
      US pharmacy groups CVS and Walgreens agree $10bn opioid settlements

      Other chains also in talks over claims linked to their roles in crisis

    • Wednesday, 2 November, 2022
      GSK PLC
      GSK lifts guidance after shingles vaccine boost

      UK drugmaker beats forecasts and ‘expects good momentum in 2023’

    • Tuesday, 1 November, 2022
      Johnson & Johnson Co Inc
      Johnson & Johnson bucks global M&A slowdown with $16.6bn Abiomed deal

      Purchase of heart pumpmaker to help US pharma group focus on drugs and medical devices

    • Thursday, 27 October, 2022
      Disease control and prevention
      Cases of drug-resistant tuberculosis rise for first time in almost 20 years

      WHO report highlights global resurgence of the disease during coronavirus pandemic

    • Monday, 24 October, 2022
      Special ReportFT Health: Communicable Diseases
      Monkeypox recedes as doctors draw lessons for future outbreaks

      Engagement with at-risk groups forms a vital part of any response

    • Monday, 10 October, 2022
      Covid-19 vaccines
      Oxford/AstraZeneca nasal Covid vaccine fails in trial

      Setback for a method hoped to provide better protection against virus transmission

    • Thursday, 6 October, 2022
      Coronavirus treatment
      Merck Covid antiviral pill did not cut hospitalisation risk, study finds

      UK trial shows ‘no difference’ between taking molnupiravir or placebo in reducing clinical admissions during Omicron wave

    • Saturday, 1 October, 2022
      Moderna
      Moderna refused China request to reveal vaccine technology

      Pharma company still ‘eager’ to collaborate with Beijing, despite collapse of initial talks

    • Saturday, 1 October, 2022
      Monkeypox
      UK health secretary rejects advice to buy extra monkeypox doses

      Coffey dismisses guidance over additional vaccines owing to value-for-money concerns

    • Thursday, 15 September, 2022
      UK politics & policy
      Thérèse Coffey’s ‘be positive’ order angers UK health workers

      New minister issues ‘patronising’ instructions, including ban on use of Oxford comma

    • Wednesday, 14 September, 2022
      Coronavirus pandemic
      Covid response of governments and WHO was ‘too slow’, says report

      Global health officials failed to quickly recommend travel restrictions and encourage use of face masks

    • Thursday, 8 September, 2022
      Disease control and prevention
      Oxford’s malaria jab spurs high, sustained protection in children

      Booster yielded efficacy as high as 80% in one group, Lancet study shows

    • Thursday, 1 September, 2022
      Covid-19 vaccines
      EU drug agency recommends approval of Covid vaccine boosters for Omicron

      EMA backs jabs targeting the strain that appeared in 2019 and original version of Omicron

    • Wednesday, 31 August, 2022
      Pharmaceuticals sector
      AstraZeneca succeeds in last-ditch bid to stop former executive starting at GSK this week

      Drugmaker sued its former head of investor relations over alleged breach of a non-compete clause

    • Thursday, 25 August, 2022
      Novartis AG
      Novartis to spin off generic drugs unit Sandoz

      Swiss group takes bold step to focus on faster-growing and higher-margin medicines

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In